Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03711227 · ClinicalTrials.gov registry record
Procalcitonin at Zero and 24 Hours as a Prognostic Factor in Patients With Pneumonia
A clinical trial of Pneumonia, sponsored by Corewell Health South.
- Completed
- Registry status
- 185
- Enrollment target
- 1
- Study location
NCT03711227: Completed study of Pneumonia, sponsored by Corewell Health South.
NCT03711227 is a study of Pneumonia that has completed, run by Corewell Health South. The registered enrollment target is 185 participants, below the 4,516-participant average among 47 other Pneumonia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03711227, a study of Pneumonia, has completed, sponsored by Corewell Health South.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
- 1
- Study location
Study Summary
Procalcitonin levels checked initially and at 24 hours will correlate with disease severity, morbidity, and mortality. Patients who have a higher procalcitonin level initially and at 24 hours will likely have higher qSOFA scores, longer lengths of stay, longer duration of antibiotics and higher 30 day mortality rates.
Primary Outcome
Change in procalcitonin level in the blood serum
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Procalcitonin lab test
Study Locations (1)
Michigan
- Lakeland Regional Healthcare - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2019-08-01 |
What the finished NCT03711227 record still lists
NCT03711227 is an observational study that tracks outcomes without assigning an intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 4,516-participant average among 47 other Pneumonia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Procalcitonin lab test is the first listed.
NCT03711227 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03711227 about?
NCT03711227 is a clinical study titled "Procalcitonin at Zero and 24 Hours as a Prognostic Factor in Patients With Pneumonia". Procalcitonin levels checked initially and at 24 hours will correlate with disease severity, morbidity, and mortality. Patients who have a higher procalcitonin level initially and at 24 hours will likely have higher qSOFA scores, longer lengths of stay, longer duration of antibiotics and higher 30 d...
What is the current status of trial NCT03711227?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2018-07-17. Estimated completion is 2019-08-01.
What conditions does trial NCT03711227 study?
This clinical trial studies the following conditions: Pneumonia.
What interventions are being tested in trial NCT03711227?
The interventions under investigation include: Procalcitonin lab test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03711227?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03711227 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03711227's enrollment target sits among peer trials
185 22nd of 47 higher than 26 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
RECRUITING
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI